finance.yahoo.com
Negativefinance.yahoo.com ·
embecta q2 earnings call highlights 154703989
ECON_ENTREPRENEURSHIPTAX_ECON_PRICEWB_1921_PRIVATE_SECTOR_DEVELOPMENTWB_346_COMPETITIVE_INDUSTRIES
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEmbecta's revenue decline is driven by share loss at a single U.S. customer and market softness in pen needles, a specific medical device consumable. The company is pursuing a small acquisition and capital return measures, but the core business faces demand and competitive pressure. The impact is company-specific and limited to the diabetes care device segment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Embecta Q2 FY2026 revenue fell 14.4% YoY to ~$222M.
- GAAP net loss of $4.1M.
- Full-year revenue guidance lowered to $1.015–1.035B (from $1.071–1.093B).
- $75M reduction linked to U.S. pen needle sales.
- Plans to acquire Owen Mumford (~$30M revenue addition); $100M buyback authorized; dividend cut to $0.01.